Sufentanil Injection and Zykadia
Determining the interaction of Sufentanil Injection and Zykadia and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression. In six healthy volunteers, pretreatment with erythromycin (500 mg twice a day for 7 days) had no significant effects on the pharmacokinetics of sufentanil (3 mcg/kg single IV dose) relative to placebo in the nine hours following administration. However, in vitro data suggest that other potent CYP450 3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir) may interfere with the metabolism of sufentanil. MANAGEMENT: Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary. References "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72 Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5
Professional:MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression. In six healthy volunteers, pretreatment with erythromycin (500 mg twice a day for 7 days) had no significant effects on the pharmacokinetics of sufentanil (3 mcg/kg single IV dose) relative to placebo in the nine hours following administration. However, in vitro data suggest that other potent CYP450 3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir) may interfere with the metabolism of sufentanil.
MANAGEMENT: Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.
- "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.
- Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72
- Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5
Generic Name: sufentanil
Brand name: Dsuvia
Synonyms: Sufentanil Sublingual Tablets, SUFentanil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Sufentanil Injection-Zylet
- Sufentanil Injection-Zylet ophthalmic
- Sufentanil Injection-Zyloprim
- Sufentanil Injection-Zymine Liquid
- Sufentanil Injection-Zymine-D
- Sufentanil Injection-Zyncof
- Zykadia-Sufentanil Sublingual Tablets
- Zykadia-Sugammadex
- Zykadia-Sugammadex Intravenous
- Zykadia-Sugammadex Sodium
- Zykadia-Sul-Ray Aloe Vera Acne Topical
- Zykadia-Sular